Nexstim Announces EUR 5 Million Investment from Brainlab and Eiffel
Summary
Nexstim has announced a EUR 5 million investment from Eiffel and Brainlab, alongside conversion of options by certain option holders. The Finnish company specializes in navigated transcranial magnetic stimulation for pre-surgical brain mapping and therapy. Brainlab's participation as a strategic investor signals growing interest from surgical navigation companies in integrating TMS into neurosurgical workflows. The funding will support continued commercialization of Nexstim's nTMS platform for both diagnostic and therapeutic applications.
Why it matters
This investment represents a significant strategic alignment between a navigated TMS pioneer and one of the world's leading surgical navigation companies. Brainlab's involvement suggests that TMS is being positioned as an integral part of the neurosurgical toolkit rather than a standalone therapy. The EUR 5M injection provides Nexstim with capital to compete more effectively in the growing pre-surgical brain mapping market where non-invasive alternatives to invasive mapping procedures are increasingly valued.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial